<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JCT</journal-id><journal-title-group><journal-title>Journal of Cancer Therapy</journal-title></journal-title-group><issn pub-type="epub">2151-1934</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jct.2012.31013</article-id><article-id pub-id-type="publisher-id">JCT-17230</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Cytotoxic Activity of &lt;i&gt;Thelesperma megapotamicum&lt;/i&gt; Organic Fractions against MCF-7 Human Breast Cancer Cell Line
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>na</surname><given-names>Cristina Figueroa</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Elio</surname><given-names>Andres Soria</given-names></name></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mónica</surname><given-names>Silvina Sanchez</given-names></name></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Juan</surname><given-names>Jose Cantero</given-names></name></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Marta</surname><given-names>Ester Goleniowski</given-names></name></contrib></contrib-group><aff id="aff1"><addr-line>Center of Excellence in Products and Processes, Córdoba, Argentina</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>anafigueroa05@yahoo.com.ar(NCF)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>02</month><year>2012</year></pub-date><volume>03</volume><issue>01</issue><fpage>103</fpage><lpage>109</lpage><history><date date-type="received"><day>November</day>	<month>5th,</month>	<year>2011</year></date><date date-type="rev-recd"><day>December</day>	<month>15th,</month>	<year>2011</year>	</date><date date-type="accepted"><day>December</day>	<month>29th,</month>	<year>2011</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Thelesperma megapotamicum (Asteraceae) is commonly used in Argentine to treat various diseases (renal, digestive affections, and as anaesthesia). The present study showed the mechanisms involved “
  in vitro” cytotoxicity of T. 
  megapotamicum Fractions. Five Fractions (F1 - F5) were separated by column chromatography (Silica gel) using hexane:diethyl ether as eluents. Viability was evaluated in Human breast carcinoma cell line (MCF-7) by staining with crystal violet. With respect to F1 Fraction treatment, the cell survival was 49.14% &#177; 8.87%, while the F2 and F3 ones exhibited a strong reduction of cell viability to only 26.35% &#177; 1.63% and 23.3%1 &#177; 0.53% of the control cell at 50 μg/ml, respectively. Apoptotic effect of these Fractions was detected using FITC-labeled Annexin V and propidium iodide binding assays and was confirmed by a higher proportion of apoptotic cells due to F2 and F3 treatments. T. 
  megapotamicum active Fractions could facilitate the tumoral cells death by decreasing the activity of the enzyme Gamma-glutamyltranspeptidase and causing alteration in cell membrane sialoglycoconjugates and others involved anticancer mechanisms including apoptosis.
 
</p></abstract><kwd-group><kwd>&lt;i&gt;Thelesperma megapotamicum&lt;/i&gt;; Cancer Breast; MCF-7 Cells; Apoptosis; Membrane Syalization; Gama-Glutamyltranspeptidase Activity</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Breast cancer is the most commonly occurring non-skin malignancy among women and the second leading cause of cancer-related death. Approximately 1 in 8.2 women will receive a diagnosis of breast cancer during her lifetime, and 1 in 30 will die of the disease [<xref ref-type="bibr" rid="scirp.17230-ref1">1</xref>].</p><p>More than 80% of the world populations use the traditional medicine to satisfy their needs of primary care of the health and that great part of the traditional treatments implies the use of extracts plants or their active principles [<xref ref-type="bibr" rid="scirp.17230-ref2">2</xref>]. In recent years, phytochemicals have been recognized as a new prevention and therapeutic approach for breast cancer [3,4].</p><p>Argentine medicinal plants have a long-standing history in many indigenous communities and are still useful resources for treating diseases. Subsequently, pharmacological studies (activity reports) are necessary in order to extend the scarce ethnopharmaceutical data, which have given empirical support to the medicinal use of these regional plants based on traditional knowledge [<xref ref-type="bibr" rid="scirp.17230-ref5">5</xref>].</p><p>Since the native flora may contain some anticancer compounds, it has become a valuable resource looking for a chemopreventive agent. Regarding this, the medical potential of Argentine plants has been recorded based on their traditional use, with an ethnobotanical survey of central Argentina being carried out over a 26-year period (1979-2005) [<xref ref-type="bibr" rid="scirp.17230-ref6">6</xref>].</p><p>Thelesperma megapotamicum belongs to Asteraceae family, it is known as Pampa tea or Indian tea [<xref ref-type="bibr" rid="scirp.17230-ref7">7</xref>]. Several compounds were isolated from this specie as stigmasterol, flavonoids (luteolin, 7-O-Glucosido, marein) and phenylpropanoids [8,9].Various studies are in line with the hypothesis that flavonoids [10,11] and phenylpropanoids [<xref ref-type="bibr" rid="scirp.17230-ref12">12</xref>] prevent or inhibit cancer development. Although, is known that luteolin has inhibitor activity of topoisomerase I in eukaryotic DNA [<xref ref-type="bibr" rid="scirp.17230-ref13">13</xref>] and DNA protector effect against oxidant agents [<xref ref-type="bibr" rid="scirp.17230-ref14">14</xref>]. Although these mechanisms have been already reported, the precise of antitumoral mode of action of T. megapotamicum compound had not been yet thoroughly studied. Probably, the cytotoxic effect produced by the extract cannot be clearly assigned to a single mechanism or a specific cellular target yet. Concerning this, several mechanisms are able to modify cellular membrane integrity that play a critical role in cell functionality, viability and apoptosis, which is relevant in carcinogenesis and oncological pharmacology [15,16].</p><p>Accordingly, the aim of this work was to elucidate the mechanisms involved in T. megapotamicum Fractions in an “in vitro” cytotoxicity representative model and also to study the effect over some membrane components.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Plant Material</title><p>Plant recollection was carried out at Santa Mar&#237;a de Punilla, “Sierras de C&#243;rdoba”. This side is located at approximately 45 km north of “C&#243;rdoba”, Argentine. Plant samples were collected during spring 2008, immediately transported to the lab and a voucher specimen was deposited in the International Herbarium of the National University of Rio Cuarto, Argentina (RIOC420).</p><p>The rhizome (12 g) was thoroughly extracted with 50 ml of hexane: ethyl ether (1:1 V/V) by maceration at room temperature for 24 hours under stirring. A supernatant was obtained by filtration, and concentrated under reduced pressure.</p></sec><sec id="s2_2"><title>2.2. Bioassay-Directed Fractionation</title><p>The hexane:diethyl ether rhizome extract was subjected to Silica gel-60 column chromatography (15.5 cm length, 0.9 cm i.d.) using hexane: ethyl ether as eluents; 50 fractions of 5 ml were checked by thin layer chromatography (TLC) and observed without chemical treatment, under UV 254 nm light. On the basis of the similar TLC profile the fractions were pooled into 5 groups: F1 - F5.</p><p>For the “in vitro” viability test, the dried Fractions were dissolved in DMSO at a concentration of 50 mg/ml.</p></sec><sec id="s2_3"><title>2.3. Cell Culture</title><p>Human breast carcinoma cell line (MCF-7, cell line ATCC HTB-22), were cultured in Dulbecco’s Modified Eagle’s medium with 10% (V/V) fetal bovine serum, 100 IU/ml penicillin G and 40 μg/ml gentamycin sulphate, incubated in a humidified atmosphere of 5% CO<sub>2</sub> at 37˚C.</p></sec><sec id="s2_4"><title>2.4. In Vitro Viability Test</title><p>After 48 hours attachment in a 96 well-plates (2 &#215; 10<sup>4</sup> cells/well) viable cells were incubated with 0 and 50 μg/ml of each Fraction (F1 - F5) for 6 hours. Afterwards, the medium containing extracts was removed and cell viability was determined by measuring the absorbance at 570 nm using crystal violet as followed. Viable cells were stained with 0.5% crystal violet in 50% methanol for 15 min. After washing with 50% methanol three times, the staining cells were solubilized with 20% methanol in sodium citrate solution (0.1 M, pH 5.4). Results, consistent with cellular density, were recorded by an Anthos Labtec 2010 micro ELISA reader at 570 nm. The viability percentage was defined as the relative absorbance of treated versus untreated control cells (100%). To compare the effectiveness of the extracts with a clinical drug, a concentration of 0.1 &#181;M of Paclitaxel and 40 &#181;M of Luteolin (Sigma Chemical Co.) were also tested as positive controls.</p></sec><sec id="s2_5"><title>2.5. Determination of Cell Death and Apoptosis</title><p>Apoptosis was analyzed by flow cytometry using fluorescein isothiocyanate (FITC)-labeled Annexin V and propidium iodide (PI) staining. Briefly, the cells were seeded in 6-well plates at a density of 1 &#215; 10<sup>6</sup> cells/ml and incubated for 24 hours at 37˚C as above. The medium was then replaced with fresh medium containing the different Fractions (0, 50 &#181;g/ml) and the cells were incubated at 37˚C for 6 hours. The cells that had become detached from the surface of the flask (floating cells), together with those which remained attached (harvested by trypsinization), were pelleted by centrifugation. Cell pellets were resuspended in complete medium (5 &#215; 10<sup>5</sup> cells/ ml), with binding buffer and incubated with FITC-labeled Annexin V and PI (at a final concentration of 1 and 2 μg/ml, respectively) for 15 min. The stained cells were analyzed on a COULTER EPICS<sup>&#174;</sup> flow cytometer. Cells negative for both FITC-labeled Annexin V and PI staining are live cells. Annexin V-positive and PI-negative staining cells are undergoing early stages of apoptosis. PIand Annexin V-positive staining cells are late apoptotic cells, and PIpositive and Annexin V-negative staining cells are necrotic cells [<xref ref-type="bibr" rid="scirp.17230-ref17">17</xref>].</p></sec><sec id="s2_6"><title>2.6. Sialic Acid Membrane Content</title><p>The MCF-7 cells were seeded at a density of 1 &#215; 10<sup>6</sup> cells/well onto 6-well culture plates and incubated for 24 hours at 37˚C, humidified air and 5% CO<sub>2</sub>. Then 50 μg/ml of the F1, F2 and F3 Fractions was added to the wells and the cells were incubated for 6 hours in the same conditions. After enzymatic harvesting with porcine trypsin, cells were homogenized at 20.000 rpm for 30 seconds in 1 ml of 10 mM HEPES buffer (pH 7.4, containing 2 μg/ml leupeptin and 1mM EDTA). They were centrifuged at 100.000 g for 1 h at 4˚C to recover the pellet, which was then resuspended in 200 μl of 10 mM HEPES buffer. The protein content was determined according to the Bradford method, and each suspension (150 μl) was mixed with 750 μl chloroform/methanol</p><p>(2:1 V/V, F&#246;lch extraction). The mixture was centrifuged at 1.000 g for 10 min, and then the upper layer was used for sialic acid determination.</p></sec><sec id="s2_7"><title>2.7. Gamma Glutamyltranspeptidase Activity</title><p>To determinate gamma glutamyltranspeptidase (γ-GT) activity the modified Szasz method was used following the γ-GT-test kinetic AA kit manufacturer’s instructions [<xref ref-type="bibr" rid="scirp.17230-ref18">18</xref>]. Samples were mixed with 1% Triton X-100 and 100 mM Tris-HCl substrate buffer, pH 8.5 (containing 2.9 mM L-γ-glutamyl-3-carboxi-4-nitroanilide and 100 mM GLY-GLY) in the proportion 1:1:9 (v/v/v). Then, the absorbance at 405 nm was recorded. Results were expressed in mIU/mg of proteins (1 IU = 1 μmole of product/min at pH 8.5 and 25˚C).</p></sec><sec id="s2_8"><title>2.8. Sialic Acid Content Measurement (Membrane Sialylation)</title><p>After F&#246;lch extraction, the Sialic acid (SA) content (nmol/mg of protein) was measured in the upper phase at 580 nm according to Miettinen and Takki-Luukkainen [<xref ref-type="bibr" rid="scirp.17230-ref19">19</xref>].</p></sec><sec id="s2_9"><title>2.9. Chemicals</title><p>Culture reagents and other chemicals were obtained from the Sigma-Aldrich Co. (USA). The γ-G-test kinetic AA kit™ for in vitro diagnosis was from Wiener Laboratories.</p></sec><sec id="s2_10"><title>2.10. Statistical Analysis</title><p>Data were expressed as mean &#177; standard deviation (SD) from four separate experiments performed in triplicate, unless otherwise noted. ANOVA models were used to evaluate differences of cellular viability and membrane parameters (γ-GT and SA) among treatments. The association between these variables was determined using the correlation coefficient (CC). Analytical probes were performed using the InfoStat 2007e.1 software.</p></sec></sec><sec id="s3"><title>3. Results</title><p>In order to evaluate the Fractions cytotoxic effect, different experiments with the MCF-7 cell line were run. The survival rates in the Fractions treated MCF-7 cells, determined by Crystal violet staining, are shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>. With regard to the results obtained, at a concentration of 50 &#181;g/ml of the F1 Fraction, following 6 hours of incubation, cell survival was 49.14% &#177; 8.87%, while the F2 and F3 ones exhibited a strong reduction of cell viability to only 26.35% &#177; 1.63% and 23.31% &#177; 0.53% of the control cell at 50 &#181;g/ml, respectively. On the other</p><p>hand, Fractions F4 and F5 had lower cytotoxic effect (77.09% &#177; 20.00% and 73.21% &#177; 7.73% survival compared to control at 50 &#181;g/ml, respectively). With regard to 0.1 &#181;M of Paclitaxel, this antitumoral drug was not cytotoxic towards the MCF-7 after 6 hours of incubation (data not shown), these results are in agreement with previous reports [<xref ref-type="bibr" rid="scirp.17230-ref17">17</xref>]. Note that by this procedure 40 &#181;M of Luteolin exhibited a 55.04% &#177; 24.24% survival relative to the control.</p><p>The apoptotic nature of T. megapotamicum Fractionsinduced cell death was confirmed using FITC-labeled Annexin V and PI binding assays as useful markers of early apoptotic and necrotic events, respectively. Stained cells were identified by flow cytometric analysis and expressed as a percentage of the total number of cells in each case.</p><p>This included cells that had become detached from the surface of the flask, as a result of poor health of the cells (including apoptotic and necrotic cells), but which had remained intact. The flow cytometric analysis excluded debris and highly condensed cells by gating on intact cells, based on light scatter. Consistent with the data shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>, not higher percentages of early apoptotic cells were detected in the different Fractions treatment and control cells. The highest percentages of advanced apoptosis were detected in cells treated with Fractions F2 and F3. A slight increase in necrosis was also seen on Fractions F2 and F3 treatments.</p><p>The lipid sialylation and the γ-GT were studied as markers of the cell membrane status. The specific activeity of γ-GT, depicted in <xref ref-type="fig" rid="fig3">Figure 3</xref> had quantifiable basal values in MCF-7. The cells treated with Fractions F1 - F3 decreased the γ-GT activity with respect to control. A decreased activity was seen with the Fraction F1 (4.8 fold lower; p ≤ 0.02), Fraction F2 (15.55 fold lower;</p><p>p ≤ 0.02), and Fraction F3 (14.7 fold lower; p ≤ 0.02) with respect to control. MCF-7 cells had basal levels of SA in their membranes of 232.2 &#177; 64.3 pmole of SA/mg of proteins, being the SA content in MCF-7 incubated with Fractions F1, F2 and F3 lower than control (p ≤ 0.05): 2.7, 3.6 and 5.7 folds respectively (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p></sec><sec id="s4"><title>4. Discussion</title><p>Carcinogenesis involves a growing accumulation of genetic and epigenetic aberrations, leading to the deregulation of cellular homeostasis, followed by neoplastic progression [<xref ref-type="bibr" rid="scirp.17230-ref20">20</xref>]. As a new approach in cancer therapy, we have investigated the effects “in vitro” of the T. megapo-</p><p>tamicum active Fractions on cells viability, γ-GT activity and membrane sialylation in MCF-7 cell culture.</p><p>The results reported herein reveal that T. megapotamicum exerts growth inhibition in cultured human breast cancer MCF-7 cells; this cell line showed a high sensibility to T. megapotamicum active organic Fractions at a very low incubation times (6 hours). We further demonstrate that these Fractions are much more effective in decreasing the cell viability compared to the commonly used chemotherapeutic agent, Paclitaxel. Previous reports shown that Paclitaxel at 0.01 and 0.1 &#181;M, did not induce significant death of these cancer cells, within 48 hours [<xref ref-type="bibr" rid="scirp.17230-ref21">21</xref>].</p><p>Our results suggest that F2 and F3 Fractions could facilitate the tumoral cells death by apoptosis, as indicated by the FITC-labeled Annexin and Propidium Iodide Fluorescence Assay. At the 50 μg/mL, for Fractions F2 and F3 on MCF-7 cells, FITC-labeled Annexin V fluorescence was detected substantially, as early as 6 hours post treatment. This showed that the plasma membrane of MCF-7 cells had incorporated FITC-labeled Annexin V, indicating that PS had been translocated from the inner to the outer leaflet of the plasma membrane (early step in apoptosis).</p><p>The γ-GT, a key enzyme of glutathione metabolism, can modulate crucial redox-sensitive functions, such as antioxidant/antitoxic defenses and cellular proliferative/ apoptotic balance, with potential implications in tumor progression and drug resistance [22,23].</p><p>Previous studies have shown the possible role of membrane γ-GT enzyme for evaluating anticancer drugs. This enzyme is located on the outer aspect of plasma membrane of most cell types, and is often expressed at high levels in malignant tumors and their metastases [<xref ref-type="bibr" rid="scirp.17230-ref24">24</xref>]. The administration of the T. megapotamicum Fractions to MCF-7 cells was reflected in a decrease of γ-GT activity. Since, γ-GT expression is regulated by the cytosolic glutathione pool and steroids [25,26], we speculated that the decreased Fractions-induced activity might generate a fewer intracellular glutathione to sustain the enzymatic activity level necessary into the cells. So, a γ-GT reduction may participate in the mechanism of Fractions sensibility and increase the apoptosis on MCF-7 cells.</p><p>Gangliosides (sialylglicolipids) have previously been found to be involved in cellular surface-relates regulation and in biomembrane resistance to oxidation [27,28]. Furthermore, since some cancer cells present aberrant glycolsilation, with the SA content being a useful tumor marker [<xref ref-type="bibr" rid="scirp.17230-ref29">29</xref>]. SA, the end moieties of the carbohydrate chains are biologically important and essential for functions of glycoconjugates and are reported to be altered in cancer patients. A positive correlation between serum levels of different forms of SA and extent of malignant disease was observed [<xref ref-type="bibr" rid="scirp.17230-ref30">30</xref>]. Glycosylation has been demonstrated to play a critical role during malignant transformation. Patients with breast cancer had significantly higher levels of different forms of SA as compared to the controls [31,32].</p><p>The basal levels of SA in cells membranes incubated with different Fractions of T. megapotamicum responded decreasing its values corresponding to a decrease in the rate of cell viability.</p><p>These data suggest that the active Fractions of T. megapotamicum, apart from their effects on cellular growth, could inhibit the expression of membrane SA.</p><p>In this work, the pharmacological regulation of Fractions could be important, since ganglioside molecular interactions are involved in cancer growth due to their role in the immune response and in the metastatic process [33,34].</p><p>Taking together, T. megapotamicum active Fractions could regulate the MCF-7 cells death by decreasing the activity of the enzyme γ-GT, and causing alteration in cell membrane sialoglycoconjugates and others involved anticancer mechanisms including apoptosis.</p><p>T. megapotamicum might contain flavonoids, such as Luteolin, and phenylpropanoids [<xref ref-type="bibr" rid="scirp.17230-ref7">7</xref>]. Previous investigators have shown that both family compounds have anticancer effects [12,35]. Meanwhile, we have not yet specifically looked into the active ingredient(s) of the T. megapotamicum that inhibits the growth of breast cancer.</p><p>In this work, organic “Pampa tea” Fractions have shown pronounced activity. Further evaluation will be done in the future for possible isolation of active anti-tumor compounds.</p></sec><sec id="s5"><title>5. Acknowledgements</title><p>This work was partially supported by grants from the Consejo Nacional de Investigaciones cient&#237;ficas y T&#233;cnicas (CONICET-AVCR) No. 962/07-05-2009.</p></sec><sec id="s6"><title>REFERENCES</title></sec><sec id="s7"><title>Abbreviations:</title><p>TLC: thin layer chromatography;</p><p>γ-GT: gamma glutamyltranspeptidase;</p><p>SA: sialic acid;</p><p>FITC: fluorescein isothiocyanate;</p><p>PI: propidium iodide;</p><p>PS: phosphatidylserine.</p></sec><sec id="s8"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.17230-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">J. D. Yager and N. E. Davidson, “Estrogen Carcinogenesis in Breast Cancer,” The New England Journal of Medicine, Vol. 354, No. 3, 2006, pp. 270-282.  
doi:10.1056/NEJMra050776</mixed-citation></ref><ref id="scirp.17230-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">A. Bermudez, M. A. Oliveira-Miranda and D. Vazquez, “La investigacion Etnobotanica Sobre Plantas Medicinales: Una Revisión de Sus Objetivos y Enfoques Actuales,” Interciencia, Vol. 30, No. 8, 2005, pp. 453-459.</mixed-citation></ref><ref id="scirp.17230-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">J. M. Cline and C. L. Hughes Jr., “Phytochemicals for the Prevention of Breast and Endometrial Cancer,” Cancer Treatment Research, Vol. 94, 1998, pp. 107-134.  
doi:10.1007/978-1-4615-6189-7_7</mixed-citation></ref><ref id="scirp.17230-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">L. S. Einbond, Y. Wen-Cai, K. He, H. Wu, E. Cruz, M. Roller and F. Kronenberg, “Growth Inhibitory Activity of Extracts and Compounds from Cimicifuga Species on Human Breast Cancer Cells,” Phytomedicine, Vol. 15, No. 6-7, 2008, pp. 504-511.  
doi:10.1016/j.phymed.2007.09.017</mixed-citation></ref><ref id="scirp.17230-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">E. L. Ratera and M. O. Ratera, “Plantas de la Flora Argentina Empleadas en Medicina Popular,” Hemisferio Sur S.A., Buenos Aires, 1980. </mixed-citation></ref><ref id="scirp.17230-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">M. Goleniowski, G. A. Bongiovanni, L. Palacio, C. O. Nunez and J. J. Cantero, “Medicinal plants from the ‘Sierra de Comechingones,’ Argentina,” Journal of Ethnopharmacoly, Vol. 107, No. 3, 2006, pp. 324-341.  
doi:10.1016/j.jep.2006.07.026</mixed-citation></ref><ref id="scirp.17230-ref7"><label>7</label><mixed-citation publication-type="book" xlink:type="simple">E. L. Ariza, “Tratamiento Taxonomico: Descripcion de Familias, Generos y Especies; Asteraceae,” In: G. E. Barboza, J. J. Cantero, C. O. Nunez and L. Ariza Espinar, Eds., Flora medicinal de la Provincia de Cordoba (Argentina), Pteridofitas y Antófitas Silvestres o Naturalizadas, Museo Botánico, Córdoba, 2006, pp. 475-477. </mixed-citation></ref><ref id="scirp.17230-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">A. Ateya, T. Okarter, J. Knapp, P. Schiff Jr. and D. Slatkin, “Flavonoids of Thelesperma megapotamicum,” Planta Medica, Vol. 45, No. 8, 1982, pp. 247-248.  
doi:10.1055/s-2007-971384</mixed-citation></ref><ref id="scirp.17230-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">V. Pathak, F. Bohlmann, R. King and H. Robinson, “Chemotaxonomy of the Genus Thelesperma,” Revista Latinoamericana de Quimica, Vol. 18, 1987, pp. 28-29.</mixed-citation></ref><ref id="scirp.17230-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">M. Hertog, P. Hollman and V. De Putte, “Content of Potentially Anticarcinogenic Flavonoids of Tea Infusions, Wines and Fruit Juices,” Journal of Agricultural and Food Chemistry, Vol. 41, No. 8, 1993, pp.1242-1246.  
doi:10.1021/jf00032a015</mixed-citation></ref><ref id="scirp.17230-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">P. Hollman, M. Hertog and M. Katan, “Analysis and Health Effects of Flavonoids,” Food Chemistry, Vol. 57, No. 1, 1996, pp. 43-46. doi:10.1016/0308-8146(96)00065-9</mixed-citation></ref><ref id="scirp.17230-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">L. G. Korkina, “Phenylpropanoids as Naturally Occurring Antioxidants: From Plant Defense to Human Health,” Cellular and Molecular Biology, Vol. 53, No. 1, 2007, pp. 15-25. </mixed-citation></ref><ref id="scirp.17230-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">A. R. Chowdhury, S. Sharma, S. Mandal, A. Goswami, S. Mukhopadhyay and H. K. Majumder, “Luteolin, an Emerging Anti-Cancer Flavonoid, Poisons Eukaryotic DNA Topoisomerase I,” Biochemical Journal, Vol. 366, No. 2, 2002, pp. 653-661. doi:10.1042/BJ20020098</mixed-citation></ref><ref id="scirp.17230-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">K. Horvathova, L. Novotny, D. Tothova and A. Vachalkova, “Determination of Free Radical Scavenging Activity of Quercetin, Rutin, Luteolin and Apigenin in H&lt;sub&gt;2&lt;/sub&gt;O&lt;sub&gt;2&lt;/sub&gt;-Treated Human ML Cell K562,” Neoplasma, Vol. 51, No. 5, 2004, pp. 395-399.</mixed-citation></ref><ref id="scirp.17230-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">K. Hossain, A. A. Akhand, M. Kato, J. Du, K. Takeda, J. H. Wu, K. Takeuchi, W. Liu, H. Suzuki and I. Nakashima, “Arsenite Induces Apoptosis of Murine T Lymphocytes through Membrane Raft-Linked Signaling for Activation of c-Jun Amino-Terminal Kinase,” Journal of Immunology, Vol. 165, No. 8, 2000, pp. 4290-4297.</mixed-citation></ref><ref id="scirp.17230-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">M. E. Pasqualini, V. L. Heyd, P. Manzo and A. R. Eynard, “Association between E-Cadherin Expression by Human Colon, Ladder and Breast Cancer Cells and the 13-HODE: 15-HETE Ratio. A Possible Role of Their Metastatic Potential,” Prostaglandins, Leukotrienes, and Essential Fatty Acids, Vol. 68, No. 1, 2003, pp. 9-16.  
doi:10.1016/S0952-3278(02)00230-2</mixed-citation></ref><ref id="scirp.17230-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">G. A. Bongiovanni, J. J. Cantero, A. Eynard and M. E. Goleniowski, “Organic Extracts of Larrea divaricata Cav. Induced Apoptosis on Tumoral MCF7 Cells with an Higher Cytotoxicity Than Nordihydroguaiaretic Acid or Paclitaxel,” Journal of Experimental Therapeutics &amp; Oncology, Vol. 7, No. 1, 2008, pp. 1-7.</mixed-citation></ref><ref id="scirp.17230-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">G. Szasz, “A Kinetic Photometric Method for Serum Gamma-Glutamyltranspeptidase,” Clinical Chemistry, Vol. 15, No.2, 1969, pp. 124-136.</mixed-citation></ref><ref id="scirp.17230-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">T. Miettinen and I. T. Takki-Luukkainen, “Use of Butyl Acetate in the Determination of Sialic Acid,” Acta Chemical Scandinava, Vol. 13, 1959, pp. 856-858.  
doi:10.3891/acta.chem.scand.13-0856</mixed-citation></ref><ref id="scirp.17230-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">P. L. Quiroga, A. R. Eynard, E. A. Soria and M. A. Valentich, “Interaction between Retinoids and Eicosanoids: Their Relevance to Cancer Chemoprevention,” Current Nutrition &amp; Food Science, Vol. 5, No. 2, 2009, pp. 126-133. doi:10.2174/157340109788185553</mixed-citation></ref><ref id="scirp.17230-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">N. S. Yaacob, N. Hamzah, N. Nursyazni, N. M. Kamal, S. A. Zainal Abidin, C. S. Lai, V. Navaratnam and M. N. Norazmi, “Anticancer Activity of a Sub-Fraction of Dichloromethane Extract of Strobilanthes crispus on Human Breast and Prostate Cancer Cells in Vitro,” BMC Complementary and Alternative Medicine, Vol. 10, 2010, pp. 42-55. doi:10.1186/1472-6882-10-42</mixed-citation></ref><ref id="scirp.17230-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">M. H. Hanigan, H. F. Frierson Jr., P. E. Swanson and B. R. De Young, “Altered Expression of Gamma-Glutamyltranspeptidase in Human Tumors,” Human Pathology, Vol. 30, No. 3, 1999, pp. 300-305.  
doi:10.1016/S0046-8177(99)90009-6</mixed-citation></ref><ref id="scirp.17230-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">A. Pompella, A. Corti, A. Paolicchi, C. Giommarelli and F. Zunino, “g-Glutamyltransferase, Redox Regulation and Cancerdrug Resistance,” Current Opinion in Pharmacology, Vol. 7, No. 4, 2007, pp. 360-366.  
doi:10.1016/j.coph.2007.04.004</mixed-citation></ref><ref id="scirp.17230-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">S. Dominici, L. Pieri, M. Comporti and A. Pompella, “Possible Role of Membrane Gamma-Glutamyltransferase Activity in the Facilitation of Transferrin-Dependent and -Independent Iron Uptake by Cancer Cells,” Cancer Cell International, Vol.3, No. 7, 2003, pp. 1-8.  
doi:10.1186/1475-2867-3-7</mixed-citation></ref><ref id="scirp.17230-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">T. H. Rasmussen, S. J. The, P. Bjerregaard and B. Korsgaard, “Anti-Estrogen Prevents Xenoestrogen-Induced Testicular Pathology of Eelpout (Zoarces viviparus),” Aquatic Toxicology, Vol. 72, No. 3, 2005, pp.177-194.  
doi:10.1016/j.aquatox.2004.12.003</mixed-citation></ref><ref id="scirp.17230-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">S. J. Chinta, J. M Kumar, H. Zhang, H. J. Forman and J. K. Andersen, “Upregulation of Gamma-Glutamyltranspeptidase Activity Following Glutathione Depletion Has a Compensatory Rather Than an Inhibitory effect on Mitochondrial Complex I Activity: Implications for Parkinson’s Disease,” Free Radical Biology &amp; Medicine, Vol. 40, No. 9, 2006, pp. 1557-1563.  
doi:10.1016/j.freeradbiomed.2005.12.023</mixed-citation></ref><ref id="scirp.17230-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">R. L. Proia, “Glycosphingolipid Functions: Insights from Engineered Mouse Models,” Philosophical Transactions of the Royal Society B: Biological Sciences, Vol. 358, No. 1433, 2003, pp. 879-883. doi:10.1098/rstb.2003.1268</mixed-citation></ref><ref id="scirp.17230-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">O. Sergent, M. Pereira, C. Belhomme, M. Chevanne, L. Huc, D. Lagadic-Gossmann, “Role for Membrane Fluidity in Ethanol-Induced Oxidative Stress of Primary Rat Hepatocytes,” The Journal of Pharmacology and Experimental Therapeutics, Vol. 313, No. 1, 2005, pp. 104-111. doi:10.1124/jpet.104.078634</mixed-citation></ref><ref id="scirp.17230-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">S. Narayanan, “Sialic Acid as a Tumor Marker,” Annals of Clinical and Laboratory Science, Vol. 24, No. 4, 1994, pp. 376-384.</mixed-citation></ref><ref id="scirp.17230-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">G. N. Raval, L. J. Parekh, D. D. Patel, F. P. Jha, R. N. Sainger and P. S. Patel, “Clinical Usefulness of Alterations in Sialic Acid, Sialyltransferase and Sialoproteins in Breast Cancer,” Indian Journal of Clinical Biochemistry, Vol. 19, No. 2, 2004, pp. 60-71. doi:10.1007/BF02894259</mixed-citation></ref><ref id="scirp.17230-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">A. Kobata and S. Takasaki, “Structural Characterization of Oligo-Saccharides from Glycoproteins,” In: M. Fukuda, and A. Kobata, Eds., Glycobiology: A practical approach, Oxford University Press, New York, 1993, pp. 165-185. </mixed-citation></ref><ref id="scirp.17230-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">A. Varki, “Biological Roles of Oligosaccharides: All of the Theories Are Correct,” Glycobiology, Vol. 3, No. 2, 1993, pp. 97-130. doi:10.1093/glycob/3.2.97</mixed-citation></ref><ref id="scirp.17230-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">S. Hakomori, “Glycosylation Defining Cancer Malignancy: New Wine in an Old Bottle,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 99, No. 16, 2002, pp. 10231-10233.  
doi:10.1073/pnas.172380699</mixed-citation></ref><ref id="scirp.17230-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">N. M Varki and A. Varki, “Diversity in Cell Surface Sialic Acid Presentations: Implications for Biology and Disease,” Laboratory Investigation, Vol. 87, No. 9, 2007, pp. 851-857. doi:10.1038/labinvest.3700656</mixed-citation></ref><ref id="scirp.17230-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">H. L. Liu, W. B. Jiang and M. X. Xie, “Flavonoids: Recent Advances as Anticancer Drugs,” Recent Patents on Anti-Cancer Drug Discovery, Vol. 5, No. 2, 2010, pp. 152-164. doi:10.2174/157489210790936261</mixed-citation></ref></ref-list></back></article>